Chief Commercial Officer Adam Zaeske said the first quarter is typically slower for the industry due to seasonal dynamics, and this year included “slightly higher market access headwinds than previous years with a higher level of plan changes, plan switching by consumers, and higher premium increases which can delay patient starts.” Still, he said demand remained strong, noting that March new prescription levels were higher than all but two months in 2025. Zaeske said the company expects the balance of 2026 ...